geneva,13thfebruary,2017—novimmune,aswissbiotechcompanyfocusedonthediscoveryanddevelopmentofantibodybaseddrugs, and legochembiosciences (lcb) (kosdaq:141080),asouthkoreancompanywithaproprietaryantibodydrugconjugate (adc)technology,haveenteredintoaresearchcollaborationtoevaluateanantibodydrugconjugatecandidate. lcbhasbeensuccessfullydevelopingglobalpartnershipsthroughthepotentialofitsproprietaryadcplatformtechnology.in2015,lcboutlicensed anantiher2adcmoleculetofosunpharmaandinjanuary2017,signedaresearchlicensingdealwithtakeda, toevaluatenextgenerationadccandidates. “ourantibodyexpertisemarriedwithlcb’sproprietaryadctechnology,supportsourquesttoprovidebetteroptionstocancerpatients”,saidnovimmunechairmanandchiefutiveofficer,eduardholdener. adcsaremoleculescomposedofatumorspecificmonoclonalantibodylinkedtoacytotoxicagent.unlikechemotherapy,theyareintendedtotargetonlycancercellsandsparehealthycells.novimmunebringsexpertiseinthefieldoftargetedtherapieswiththeiranticd47anticd19andanticd47antimesothelinbispecificantibodiesthativelybindtohematologicalandsolidtumors,respectively. aboutnovimmune novimmunesaisaprivatelyheld,swissbiopharmaceuticalcompanyfocusedonthediscoveryanddevelopmentofantibodybaseddrugsforthetargetedtreatmentofinflammatorydiseases,immunerelateddisorders,andcancer.thecompanyisheadquarteredingenevaandcurrentlyemploys130people. moreinformationisavailableonthecompanywebsiteat www.novimmune.com. contact:adrianmills+41(0)612011327amills@novimmune.com
lcbhasbeensuccessfullydevelopingglobalpartnershipsthroughthepotentialofitsproprietaryadcplatformtechnology.in2015,lcboutlicensed anantiher2adcmoleculetofosunpharmaandinjanuary2017,signedaresearchlicensingdealwithtakeda, toevaluatenextgenerationadccandidates. “ourantibodyexpertisemarriedwithlcb’sproprietaryadctechnology,supportsourquesttoprovidebetteroptionstocancerpatients”,saidnovimmunechairmanandchiefutiveofficer,eduardholdener. adcsaremoleculescomposedofatumorspecificmonoclonalantibodylinkedtoacytotoxicagent.unlikechemotherapy,theyareintendedtotargetonlycancercellsandsparehealthycells.novimmunebringsexpertiseinthefieldoftargetedtherapieswiththeiranticd47anticd19andanticd47antimesothelinbispecificantibodiesthativelybindtohematologicalandsolidtumors,respectively. aboutnovimmune novimmunesaisaprivatelyheld,swissbiopharmaceuticalcompanyfocusedonthediscoveryanddevelopmentofantibodybaseddrugsforthetargetedtreatmentofinflammatorydiseases,immunerelateddisorders,andcancer.thecompanyisheadquarteredingenevaandcurrentlyemploys130people. moreinformationisavailableonthecompanywebsiteat www.novimmune.com. contact:adrianmills+41(0)612011327amills@novimmune.com
“ourantibodyexpertisemarriedwithlcb’sproprietaryadctechnology,supportsourquesttoprovidebetteroptionstocancerpatients”,saidnovimmunechairmanandchiefutiveofficer,eduardholdener. adcsaremoleculescomposedofatumorspecificmonoclonalantibodylinkedtoacytotoxicagent.unlikechemotherapy,theyareintendedtotargetonlycancercellsandsparehealthycells.novimmunebringsexpertiseinthefieldoftargetedtherapieswiththeiranticd47anticd19andanticd47antimesothelinbispecificantibodiesthativelybindtohematologicalandsolidtumors,respectively. aboutnovimmune novimmunesaisaprivatelyheld,swissbiopharmaceuticalcompanyfocusedonthediscoveryanddevelopmentofantibodybaseddrugsforthetargetedtreatmentofinflammatorydiseases,immunerelateddisorders,andcancer.thecompanyisheadquarteredingenevaandcurrentlyemploys130people. moreinformationisavailableonthecompanywebsiteat www.novimmune.com. contact:adrianmills+41(0)612011327amills@novimmune.com
adcsaremoleculescomposedofatumorspecificmonoclonalantibodylinkedtoacytotoxicagent.unlikechemotherapy,theyareintendedtotargetonlycancercellsandsparehealthycells.novimmunebringsexpertiseinthefieldoftargetedtherapieswiththeiranticd47anticd19andanticd47antimesothelinbispecificantibodiesthativelybindtohematologicalandsolidtumors,respectively. aboutnovimmune novimmunesaisaprivatelyheld,swissbiopharmaceuticalcompanyfocusedonthediscoveryanddevelopmentofantibodybaseddrugsforthetargetedtreatmentofinflammatorydiseases,immunerelateddisorders,andcancer.thecompanyisheadquarteredingenevaandcurrentlyemploys130people. moreinformationisavailableonthecompanywebsiteat www.novimmune.com. contact:adrianmills+41(0)612011327amills@novimmune.com
aboutnovimmune novimmunesaisaprivatelyheld,swissbiopharmaceuticalcompanyfocusedonthediscoveryanddevelopmentofantibodybaseddrugsforthetargetedtreatmentofinflammatorydiseases,immunerelateddisorders,andcancer.thecompanyisheadquarteredingenevaandcurrentlyemploys130people. moreinformationisavailableonthecompanywebsiteat www.novimmune.com. contact:adrianmills+41(0)612011327amills@novimmune.com
novimmunesaisaprivatelyheld,swissbiopharmaceuticalcompanyfocusedonthediscoveryanddevelopmentofantibodybaseddrugsforthetargetedtreatmentofinflammatorydiseases,immunerelateddisorders,andcancer.thecompanyisheadquarteredingenevaandcurrentlyemploys130people. moreinformationisavailableonthecompanywebsiteat www.novimmune.com. contact:adrianmills+41(0)612011327amills@novimmune.com
contact:adrianmills+41(0)612011327amills@novimmune.com
adrianmills+41(0)612011327amills@novimmune.com
+41(0)612011327amills@novimmune.com
amills@novimmune.com
